Incyte (INCY) News Today → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free incy Stock Alerts $58.18 +0.78 (+1.36%) (As of 02:58 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 21 at 7:40 PM | bizjournals.comIncyte buys 2 buildings in downtown Wilmington for major expansion, moving 300 jobs from Chadds FordMay 21 at 1:15 PM | businesswire.comIncyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office BuildingsMay 21 at 7:05 AM | marketbeat.comIncyte Q1 Earnings TranscriptMay 21 at 6:34 AM | marketbeat.comGreat Lakes Advisors LLC Purchases Shares of 32,382 Incyte Co. (NASDAQ:INCY)Great Lakes Advisors LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 32,382 shares of the biopharmaceutical company's stock,May 20 at 4:31 PM | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Acquired by Trexquant Investment LPTrexquant Investment LP increased its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 82.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 295,414 shares of the biopharmaceMay 18, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Holdings Decreased by Robeco Institutional Asset Management B.V.Robeco Institutional Asset Management B.V. trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 32.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 586,653 shares of the biopharmaceutical company's stock afterMay 16, 2024 | markets.businessinsider.comIncyte’s Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold RatingMay 15, 2024 | msn.comIncyte’s stock rallies 9% after company says to buy back $1.67 billion of its own stock in Dutch auction tenderMay 15, 2024 | marketbeat.comIncyte (NASDAQ:INCY) Sees Large Volume IncreaseIncyte (NASDAQ:INCY) Sees Strong Trading VolumeMay 15, 2024 | wsj.comStocks to Watch Monday: GameStop, AMC, Squarespace, IncyteMay 15, 2024 | forbes.comHow Does Incyte Stock’s Decline During The 2022 Inflation Shock Compare With The 2008 Crash?May 15, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 26,818 Shares of Incyte Co. (NASDAQ:INCY)BNP Paribas Financial Markets boosted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,258 shares of the biopharmaceutical compMay 14, 2024 | businesswire.comIncyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressMay 14, 2024 | finance.yahoo.comCompany News For May 14, 2024May 14, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Moran Wealth Management LLCMoran Wealth Management LLC trimmed its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 44.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,451 shares of the biopharmaceutical companyMay 14, 2024 | marketwatch.comStock Market Today: Dow snaps 8-day winnning streakMay 14, 2024 | finance.yahoo.comHeard on the Street Monday Recap: Hello KittyMay 14, 2024 | benzinga.comGameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On MondayMay 14, 2024 | marketwatch.comIncyte Shares Rally on $2 Billion Buyback PlansMay 14, 2024 | msn.comIncyte Stock Marks Biggest Jump in 7 Years on ‘Dutch Auction’ Buyback Plan. How It Works.May 13, 2024 | marketwatch.comStock Market Today: Dow trades higher as S&P 500 nudges toward record territoryMay 13, 2024 | investopedia.comS&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback PlanMay 13, 2024 | marketbeat.comIncyte (NASDAQ:INCY) Shares Gap Up to $53.06Incyte (NASDAQ:INCY) Shares Gap Up to $53.06May 13, 2024 | marketbeat.comQsemble Capital Management LP Cuts Holdings in Incyte Co. (NASDAQ:INCY)Qsemble Capital Management LP cut its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 88.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,739 shares of the biopharmaMay 13, 2024 | marketwatch.comIncyte Sets $2 Billion Stock BuybackMay 13, 2024 | msn.comIncyte to buy back $1.67 billion of its own stock in Dutch auction tenderMay 13, 2024 | businesswire.comIncyte Announces Intention to Buy Back up to $2.0 Billion of its Common StockMay 12, 2024 | marketbeat.comJump Financial LLC Increases Stock Holdings in Incyte Co. (NASDAQ:INCY)Jump Financial LLC raised its position in Incyte Co. (NASDAQ:INCY - Free Report) by 1,562.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,448 shares of the biopharmaceutical companyMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 8, 2024 | marketbeat.comSwiss National Bank Lowers Holdings in Incyte Co. (NASDAQ:INCY)Swiss National Bank trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 595,600 shares of the biopharmaceutical company's stock after selling 14,400 shares duriMay 4, 2024 | finance.yahoo.comIncyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 4, 2024 | marketbeat.comLSV Asset Management Acquires 1,465,792 Shares of Incyte Co. (NASDAQ:INCY)LSV Asset Management lifted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 119.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,691,827 shares of the biopharmaceutical company's stock after purchasing an additional 1,465,792 sharMay 3, 2024 | marketbeat.comAnalysts Set Expectations for Incyte Co.'s Q2 2024 Earnings (NASDAQ:INCY)Incyte Co. (NASDAQ:INCY - Free Report) - Investment analysts at William Blair decreased their Q2 2024 earnings per share (EPS) estimates for shares of Incyte in a report issued on Tuesday, April 30th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earningMay 3, 2024 | marketbeat.comVan ECK Associates Corp Sells 37,941 Shares of Incyte Co. (NASDAQ:INCY)Van ECK Associates Corp trimmed its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 19.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,540 shares of the biopharmaceutical compMay 2, 2024 | marketbeat.comLos Angeles Capital Management LLC Buys 424,934 Shares of Incyte Co. (NASDAQ:INCY)Los Angeles Capital Management LLC boosted its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 37.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,570,296 shares of the biopharmaceutical company's stoMay 2, 2024 | businesswire.comIncyte to Present at Upcoming Investor ConferenceMay 1, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Incyte (INCY)May 1, 2024 | marketbeat.comTD Cowen Cuts Incyte (NASDAQ:INCY) Price Target to $80.00TD Cowen dropped their target price on shares of Incyte from $88.00 to $80.00 and set a "buy" rating on the stock in a report on Wednesday.May 1, 2024 | marketbeat.comIncyte (NASDAQ:INCY) Earns Buy Rating from Truist FinancialTruist Financial reiterated a "buy" rating and set a $83.00 price target (down previously from $84.00) on shares of Incyte in a research report on Wednesday.April 30, 2024 | markets.businessinsider.comIncyte Corporation Q1 Profit Increases, but misses estimatesApril 30, 2024 | msn.comIncyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75MApril 30, 2024 | marketbeat.comIncyte (NASDAQ:INCY) Shares Gap Down to $52.56Incyte (NASDAQ:INCY) Shares Gap Down to $52.56April 30, 2024 | reuters.comIncyte misses quarterly profit on weak sales of lead drugApril 30, 2024 | finance.yahoo.comIncyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in ...April 30, 2024 | seekingalpha.comIncyte Corporation 2024 Q1 - Results - Earnings Call PresentationApril 30, 2024 | businesswire.comIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsApril 30, 2024 | markets.businessinsider.comWhat Wall Street expects from Incyte's earningsApril 29, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Incyte (INCY)April 29, 2024 | marketbeat.comRussell Investments Group Ltd. Raises Holdings in Incyte Co. (NASDAQ:INCY)Russell Investments Group Ltd. grew its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 29.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 963,090 shares of the biopharmaceutical company's stock after aApril 27, 2024 | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Sold by Sector Gamma ASSector Gamma AS trimmed its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 7.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 398,699 shares of the biopharmaceutical company's stock after sellin Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address WARNING about the death of the U.S. dollar… (Ad)Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!) Get Colonial Metals' new Precious Metals Investment Guide. INCY Media Mentions By Week INCY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼0.430.44▲Average Medical News Sentiment INCY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼118▲INCY Articles Average Week Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Medpace News Today Charles River Laboratories International News Today Exelixis News Today National Research News Today ICON Public News Today IQVIA News Today Fresenius Medical Care News Today Natera News Today Revvity News Today Bio-Techne News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 5/22/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Presidential candidate you should REALLY be worried aboutStansberry ResearchThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThis military-backed stock “owns” AI marketPorter & CompanyLittle-known biotech company just had groundbreaking results from a studySmallcaps DailyBill Clinton Backing Biden Replacement???The Freeport SocietyThe Crypto 9-5 Escape PlanCrypto 101 Media**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.